SD-169

SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation[1].

Product Specifications

CAS Number

[1670-87-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

P38 MAPK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/sd-169.html

Purity

99.44

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC2=C(NC=C2)C=C1)N

Molecular Formula

C9H8N2O

Molecular Weight

160.18

Precautions

H302, H315, H319, H335

References & Citations

[1]Medicherla S, et al. Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes. J Pharmacol Exp Ther. 2006 Jul;318 (1) :99-107.